Recon: Siemens Healthineers seeks takeover of Novartis’ molecular imaging business; FDA expands probe into Lykos MDMA drug studies

• Biden administration’s $3.2 billion antiviral pandemic plan is fizzling out (STAT)
• U.S. agency slaps down a J&J plan to switch payments for 340B hospitals (STAT)
• FDA Widens Probe of Ecstasy-Based Drug Studies (WSJ) (Reuters)
• Mpox vaccine collab; $11M oncology seed; Gates backs RSV vaccine; Kyowa Kirin slims portfolio (Endpoints)
• US Presidential Elections: Are Prescription Drug Pricing Reforms Losing Political Luster? (Pink Sheet)
• McKesson to buy controlling stake in Florida Cancer Specialists' unit for about $2.5 billion (Reuters)
• Cigna to remove AbbVie's Humira from some drug reimbursement lists next year (Reuters)

• Regeneron wins EU approval for lymphoma bispecific following FDA rejection (Endpoints)
• Belgium's UCB to sell China neurology, allergy business for $680 mln (Reuters) (Endpoints)
• Progress Or Hype? Looking At A Decade Of Cell Therapy In Japan (Pink Sheet)
• WHO To Finalize Preferred & Critical Characteristics Of New Mpox Human Vaccines (Pink Sheet)
• Regulatory tracker: Merck's blockbuster-to-be PAH drug Winrevair wins EC nod (Fierce Pharma)
• Bayer to Lay Off 150 in Basel, Switzerland (BioSpace)
• Missed Warnings, $100 Vaccines and Red Tape — Why Mpox Was an Avoidable Emergency (Bloomberg)
• LinkedIn post lands Vertex in hot water with MHRA over breach of UK ad regulations (Fierce Pharma)
• Novartis receives binding offer from Siemens Healthineers for molecular imaging business (Reuters)

• A Galapagos investor signals impatience with its turnaround efforts (STAT)
• Tome Biosciences files notice to lay off virtually entire staff (STAT)
• Once one of immuno-oncology's next great hopes, CD47 faces final shots on goal (Endpoints)
• GSK’s Bexsero Dangles No More: Meningococcal B Vaccine Converts To Regular Approval (Pink Sheet)
• With new focus, Kyowa Kirin pulls decades-old breast cancer drug Fareston from US market (Fierce Pharma)

• Dexcom launches over-the-counter continuous glucose sensors in the US (Reuters          )
• Continuous glucose monitoring for the masses is here. Are we ready for it? (STAT)
• Defibtech recalls chest compression device linked to patient death (MedTech Dive)
• Getinge to buy Paragonix organ-preserving tech for up to $477M (MedTech Dive)
• Stryker to add back pain treatment with Vertos Medical buy (MedTech Dive)
• Quest inks deal for University Hospitals’ outreach lab services (MedTech Dive)
• Getinge To Acquire Paragonix Technologies For About $477M (MedTech Insight)
• Diagnostics firm Labcorp weighs ramping up mpox testing capacity (Reuters)

• Better Coverage For Cancer Screening Tests On Horizon (MedTech Insight)
• Would Trump Repeal the Inflation Reduction Act if Elected? (BioSpace)
• HHS kicks off vaccine awareness campaign to reduce risk of COVID, flu and RSV (Fierce Pharma)